<DOC>
	<DOC>NCT01777152</DOC>
	<brief_summary>This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.</brief_summary>
	<brief_title>ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with newly diagnosed, CD30positive mature Tcell lymphomas Fluorodeoxyglucose (FDG)avid disease by PET and measurable disease of at least 1.5 cm by CT Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 History of another primary invasive malignancy that has not been in remission for at least 3 years Current diagnosis of primary cutaneous CD30positive Tcell lymphoproliferative disorders and lymphomas or mycosis fungoides History of progressive multifocal leukoencephalopathy (PML) Cerebral/meningeal disease related to the underlying malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD30</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Lymphoma, T-Cell</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
</DOC>